MorphoSys AG

(NASDAQ:MOR)

Latest On MorphoSys AG (MOR):

Date/Time Type Description Signal Details
2023-05-22 16:40 ESTNewsMorphoSys: Morphing Prospects, Q1 2023, Rising From The AshesN/A
2023-05-06 10:41 ESTNewsMorphoSys AG (MOR) Q1 2023 Earnings Call TranscriptN/A
2023-05-03 19:07 ESTNewsMorphoSys GAAP EPS of -€1.30, revenue of €62.3M; reaffirms FY22 guidanceN/A
2023-04-13 14:37 ESTNewsMorphoSys: Pelabresib Data Expected In Year-End 2023, Upgrading To A BuyN/A
2023-04-05 17:04 ESTNewsMorphoSys adds 16% on faster timeline for Phase 3 myelofibrosis programN/A
2023-03-16 12:13 ESTNewsMorphoSys AG (MOR) Q4 2022 Earnings Call TranscriptN/A
2023-03-16 12:13 ESTNewsMorphoSys AG 2022 Q4 - Results - Earnings Call PresentationN/A
2023-03-15 21:19 ESTNewsMorphoSys GAAP EPS of €8.93, revenue of €81.6MN/A
2023-03-15 05:58 ESTNewsMorphoSys announces Lucinda Crabtree to join as CFON/A
2023-03-02 11:09 ESTNewsMorphoSys ends pre-clinical research in favor of clinical-stage cancer programsN/A
2023-02-01 11:54 ESTNewsMorphoSys: Negative Enterprise Value Biotech, But Lack Of Near-Term CatalystN/A
2023-01-06 20:25 ESTNewsMorphoSys AG: Staying On The SidelinesN/A
2022-12-28 06:57 ESTNewsInnoCare tafasitamab combo gets approval in Hong Kong for blood cancer subtypeN/A
2022-11-17 15:04 ESTNewsMorphoSys AG (MOR) Q3 2022 Earnings Call TranscriptN/A
2022-11-16 22:41 ESTNewsMorphoSys GAAP EPS of -€3.60, revenue of €95.8MN/A
2022-10-24 16:32 ESTNewsMorphoSys sees red as Deutsche Bank downgrades stockN/A
2022-10-24 16:32 ESTNewsGerman biotech MorphoSys falls 10% after twin downgrades in EuropeN/A
2022-10-21 17:31 ESTNewsMorphoSys lowers FY22 sales outlook for cancer drug Monjuvi on competition woesN/A
2022-08-06 19:19 ESTNewsMorphoSys AG (MOR) CEO Jean-Paul Kress on Q2 2022 Results - Earnings Call TranscriptN/A
2022-08-04 05:54 ESTNewsMorphoSys GAAP EPS of -€10.47, revenue of €100.9MN/A
2022-07-26 11:14 ESTNewsMorphoSys updates Q2 & FY22 guidance below prior provided levelsN/A
2022-06-15 19:50 ESTNewsHot Stocks: FIVE rises on buybacks, SKX gains on upgrade, MOR also trends higher and MEI declinesN/A
2022-06-15 03:05 ESTNewsMorphoSys, HIBio enter into licensing agreements for two of MorphoSys' antibodiesN/A
2022-05-09 04:25 ESTNewsMorphoSys AG (MOR) CEO Jean-Paul Kress on Q1 2022 Results - Earnings Call TranscriptN/A
2022-05-04 18:46 ESTNewsMorphoSys GAAP EPS of -€3.59, revenue of €41.5MN/A
2022-05-04 18:46 ESTNewsMorphoSys May Not Recover From Adventurous Constellation BuyoutN/A
2022-03-25 08:49 ESTNewsMorphoSys stock rises after Berenberg starts coverageN/A
2022-03-23 23:26 ESTNewsMorphoSys slips as Deutsche Bank and Citi cut price targetsN/A
2022-03-23 23:26 ESTNewsMorphoSys rises after Swissmedic grants temporary approval to lymphoma treatmentN/A
2022-03-18 07:31 ESTNewsMorphoSys AG (MOR) CEO Jean-Paul Kress on Q4 2021 Results - Earnings Call TranscriptN/A
2022-03-16 20:52 ESTNewsMorphoSys reports FY resultsN/A
2022-03-11 04:50 ESTNewsMorphoSys to recognize nearly €231M charge related to Constellation acquisitionN/A
2022-01-28 18:10 ESTNewsSierra Oncology's Strong Data In Myelofibrosis Challenges MorphoSys And IncyteN/A
2022-01-18 15:05 ESTNewsMorphoSys dips 2% after providing 2022 guidanceN/A
2021-12-08 18:19 ESTNewsWarning: MOR is at high risk of performing badlyN/A
2021-11-11 18:36 ESTNewsMorphoSys AG 2021 Q3 - Results - Earnings Call PresentationN/A
2021-11-11 18:36 ESTNewsMorphoSys AG (MOR) CEO Jean-Paul Kress on Q3 2021 Results - Earnings Call TranscriptN/A
2021-09-27 09:18 ESTNewsMorphoSys cut to Neutral at Citi, analyst sees few short-term catalystsN/A
2021-08-27 01:28 ESTNewsEuropean Commission grants conditional approval to Incyte and MorphoSys' Minjuvi comboN/A
2021-07-31 20:26 ESTNewsMorphoSys AG (MOR) CEO Jean-Paul Kress on Q2 2021 Results - Earnings Call TranscriptN/A
2021-07-31 20:26 ESTNewsMorphoSys AG 2021 Q2 - Results - Earnings Call PresentationN/A
2021-07-29 10:52 ESTNewsMorphoSys reports Q2 resultsN/A
2021-07-26 10:08 ESTNewsMorphoSys dips after narrowing 2021 revenue guidanceN/A
2021-07-22 14:47 ESTNewsMorphoSys upgraded at Morgan Stanley, Aveanna wins positive views; and more in today’s analyst actionN/A
2021-07-22 14:47 ESTNewsMorphoSys to acquire Constellation Pharma for $1.7B in cashN/A
2021-07-22 14:47 ESTNewsEpizyme gains as peer Constellation attracts sizable premium from MorphoSysN/A
2021-07-22 14:46 ESTNewsIncyte and MorphoSys present new three-year data for blood cancer therapyN/A
2021-07-22 14:46 ESTNewsCureVac downgraded following COVID vaccine data, Regeneron COVID cocktail a boon, and more in analyst actionN/A
2021-07-22 14:46 ESTNewsIncyte/Morphosys' tafasitamab gets CHMP opinion to treat certain patients with lymphomaN/A
2021-07-22 14:45 ESTNewsConstellation Pharmaceuticals says HSR waiting period expired for its planned sale to MorphoSysN/A

About MorphoSys AG (MOR):

MorphoSys AG, together with its subsidiaries, develops and commercializes antibodies and peptides for therapeutic applications in the United States. Its lead product candidate is Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B cell lymphoma and chronic lymphocytic leukemia. The company develops Tremfya, an antibody to treat plaque psoriasis, psoriatic arthritis, Crohn's disease, ulcerative colitis, hidradenitis suppurativa, and adenomatous polyposis diseases; Gantenerumab, an antibody for the treatment of Alzheimer's diseases through its pharmaceutical partners; MOR202, an antibody for the treatment of multiple myeloma and other cancers, as well as other autoimmune diseases; Otilimab, an antibody for rheumatoid arthritis; MOR106, an antibody for inflammatory diseases and atopic dermatitis; and MOR107, a lanthipeptide for oncology diseases. MorphoSys AG has a regional licensing agreement with I-Mab Biopharma to develop and commercialize MOR202 in China, Taiwan, Hong Kong, and Macau; a strategic alliance with the LEO Pharma A/S to develop peptide-derived therapeutics for unmet medical needs; a joint collaboration and license agreement with Incyte Corporation for the development and commercialization of MorphoSys investigational compound tafasitamab (MOR208); and a clinical collaboration with Incyte Corporation and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was founded in 1992 and is headquartered in Planegg, Germany.

MOR Quotes by TradingView

See Advanced Chart

General

  • Name MorphoSys AG
  • Symbol MOR
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 640
  • Fiscal Year EndDecember
  • IPO Date1999-03-09
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://www.morphosys.com
View More

Valuation

  • Trailing PE 45.88
  • Forward PE 322.58
  • Price/Sales (Trailing 12 Mt.) 7.94
  • Price/Book (Most Recent Quarter) 4.14
  • Enterprise Value Revenue 6.33
  • Enterprise Value EBITDA 16.33
View More

Financials

  • Most Recent Quarter 2020-09-30
  • Next Quarter EPS Estimate -$0.71
  • Profit Margin 30%
  • Return on Assets 2%
  • Return on Equity 19%
  • Earnings Per Share -$0.26
  • Revenue Per Share $0
  • Gross Profit 318.52 million
  • Quarterly Earnings Growth 225.4%
View More

Highlights

  • Market Capitalization 2.87 billion
  • Analyst Target Price $36.68
  • Book Value Per Share $4.90
View More

Share Statistics

  • Shares Outstanding 131.04 million
  • Shares Float 126.93 million
  • % Held by Insiders <1%
  • % Held by Institutions 3.09%
  • Shares Short 327762
  • Shares Short Prior Month 321881
  • Short Ratio 7.65
View More

Technicals

  • Beta 0.85
  • 52 Week High $35.73
  • 52 Week Low $20.57
  • 50 Day Moving Average 26.83
  • 200 Day Moving Average 28.16
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

MorphoSys AG (MOR) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

MorphoSys AG (MOR) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-09-302020-11-11$22 million-$0.58
2020-06-302020-09-30$N/A-$2.34-$2.00-17.08%
2020-03-312020-06-30$N/A-$1.82$1.09-267.39%
2019-12-312020-03-31$12.42 million$7.97-$1.52624.53%
2019-09-302019-12-31$13.59 million-$1.78
2019-06-302019-09-30$39.11 million-$0.83-$1.1929.75%
2019-03-312019-05-07$15.19 million-$0.20
2018-12-312019-03-13$12.03 million-$0.39
2018-09-302018-11-05$63.71 million$0.27$0.2223.09%
2018-06-302018-08-01$6.16 million-$0.21-$0.222.36%
2018-03-312018-05-02$2.8 million-$0.21

MorphoSys AG (MOR) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

MorphoSys AG (MOR) Chart:

MorphoSys AG (MOR) News:

Below you will find a list of latest news for MorphoSys AG (MOR) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

MorphoSys AG (MOR) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2026-01-162.50CALL0 00FALSE00
2026-01-1650CALL0 0173.69FALSE00
2026-01-167.50CALL0 0118.11FALSE00
2026-01-16100CALL0 085.73FALSE00
2026-01-1612.56.7CALL0 062.69FALSE00
2026-01-16153.5CALL0 723.45FALSE00
2026-01-1617.51.65CALL0 70FALSE00
2026-01-16200.2CALL0 11850FALSE00
2026-01-1622.50.05CALL0 775.93FALSE00
2026-01-16250CALL0 00FALSE00
2026-01-16300CALL0 00FALSE00
2026-01-16350.05CALL0 50FALSE00
2026-01-162.50PUT0 00TRUE00
2026-01-1650.05PUT0 10TRUE00
2026-01-167.50.05PUT0 520TRUE00
2026-01-16100.1PUT0 110TRUE00
2026-01-1612.50.05PUT0 4023.34TRUE00
2026-01-16150.05PUT0 40TRUE00
2026-01-1617.50.15PUT0 113410.35TRUE00
2026-01-16200PUT0 00TRUE00
2026-01-1622.50PUT0 021.79TRUE00
2026-01-16250PUT0 028.99TRUE00
2026-01-16300PUT0 040.33TRUE00
2026-01-16350PUT0 049.37TRUE00

MorphoSys AG (MOR) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-05-286-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1340243/000119312520153787/0001193125-20-153787-index.htm
2020-02-07SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1340243/000031506620001086/0000315066-20-001086-index.htm
2020-02-07SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1340243/000083423720008264/0000834237-20-008264-index.htm
2020-10-09SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1340243/000083423720010362/0000834237-20-010362-index.htm
2019-04-036-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1340243/000119312519096035/0001193125-19-096035-index.htm
2019-04-086-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1340243/000119312519099837/0001193125-19-099837-index.htm
2019-04-126-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1340243/000119312519104424/0001193125-19-104424-index.htm
2019-04-186-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1340243/000119312519109794/0001193125-19-109794-index.htm
2019-04-256-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1340243/000119312519117791/0001193125-19-117791-index.htm
2019-04-256-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1340243/000119312519117802/0001193125-19-117802-index.htm
2019-05-066-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1340243/000119312519137502/0001193125-19-137502-index.htm
2019-05-096-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1340243/000119312519142122/0001193125-19-142122-index.htm
2019-05-176-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1340243/000119312519149873/0001193125-19-149873-index.htm
2019-06-246-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1340243/000119312519179274/0001193125-19-179274-index.htm
2019-06-256-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1340243/000119312519180638/0001193125-19-180638-index.htm
2019-06-266-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1340243/000119312519181770/0001193125-19-181770-index.htm
2019-07-036-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1340243/000119312519188873/0001193125-19-188873-index.htm
2019-07-106-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1340243/000119312519191530/0001193125-19-191530-index.htm
2019-07-106-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1340243/000119312519191535/0001193125-19-191535-index.htm
2019-08-086-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1340243/000119312519215967/0001193125-19-215967-index.htm
2019-08-086-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1340243/000119312519215970/0001193125-19-215970-index.htm
2019-08-086-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1340243/000119312519215972/0001193125-19-215972-index.htm
2019-08-096-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1340243/000119312519217375/0001193125-19-217375-index.htm
2019-09-176-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1340243/000119312519246175/0001193125-19-246175-index.htm
2019-10-116-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1340243/000119312519266207/0001193125-19-266207-index.htm
2019-10-156-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1340243/000119312519267265/0001193125-19-267265-index.htm
2019-10-296-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1340243/000119312519277114/0001193125-19-277114-index.htm
2019-10-306-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1340243/000119312519278283/0001193125-19-278283-index.htm
2019-10-306-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1340243/000119312519278513/0001193125-19-278513-index.htm
2019-11-076-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1340243/000119312519286528/0001193125-19-286528-index.htm
2019-11-076-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1340243/000119312519286530/0001193125-19-286530-index.htm
2019-11-076-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1340243/000119312519287076/0001193125-19-287076-index.htm
2019-11-126-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1340243/000119312519289163/0001193125-19-289163-index.htm
2019-11-196-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1340243/000119312519295098/0001193125-19-295098-index.htm
2019-11-206-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1340243/000119312519296004/0001193125-19-296004-index.htm
2019-12-036-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1340243/000119312519304878/0001193125-19-304878-index.htm
2020-01-026-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1340243/000119312520000132/0001193125-20-000132-index.htm
2020-01-026-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1340243/000119312520000133/0001193125-20-000133-index.htm
2020-01-136-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1340243/000119312520006025/0001193125-20-006025-index.htm
2020-02-056-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1340243/000119312520024924/0001193125-20-024924-index.htm
2020-03-026-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1340243/000119312520057919/0001193125-20-057919-index.htm
2020-03-046-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1340243/000119312520061141/0001193125-20-061141-index.htm
2020-03-056-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1340243/000119312520062175/0001193125-20-062175-index.htm
2020-03-1820-FAnnual and transition report of foreign private issuers [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1340243/000119312520077290/0001193125-20-077290-index.htm
2020-03-206-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1340243/000119312520079859/0001193125-20-079859-index.htm
2020-03-206-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1340243/000119312520080448/0001193125-20-080448-index.htm
2020-03-276-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1340243/000119312520088544/0001193125-20-088544-index.htm
2020-04-076-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1340243/000119312520099897/0001193125-20-099897-index.htm
2020-04-236-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1340243/000119312520116274/0001193125-20-116274-index.htm
2020-04-246-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1340243/000119312520118506/0001193125-20-118506-index.htm
2020-04-286-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1340243/000119312520122404/0001193125-20-122404-index.htm
2020-05-066-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1340243/000119312520134923/0001193125-20-134923-index.htm
2020-05-086-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1340243/000119312520136864/0001193125-20-136864-index.htm
2020-05-156-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1340243/000119312520143549/0001193125-20-143549-index.htm
2020-05-226-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1340243/000119312520149251/0001193125-20-149251-index.htm
2020-05-226-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1340243/000119312520149262/0001193125-20-149262-index.htm
2020-05-286-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1340243/000119312520153787/0001193125-20-153787-index.htm
2020-07-156-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1340243/000119312520193110/0001193125-20-193110-index.htm
2020-08-036-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1340243/000119312520207805/0001193125-20-207805-index.htm
2020-08-056-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1340243/000119312520210666/0001193125-20-210666-index.htm
2020-08-076-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1340243/000119312520212764/0001193125-20-212764-index.htm
2020-08-256-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1340243/000119312520229194/0001193125-20-229194-index.htm
2020-09-186-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1340243/000119312520248652/0001193125-20-248652-index.htm
2020-09-186-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1340243/000119312520248657/0001193125-20-248657-index.htm
2020-09-306-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1340243/000119312520258983/0001193125-20-258983-index.htm
2020-10-016-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1340243/000119312520260398/0001193125-20-260398-index.htm
2020-10-076-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1340243/000119312520265157/0001193125-20-265157-index.htm
2020-10-136-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1340243/000119312520268438/0001193125-20-268438-index.htm
2020-10-196-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1340243/000119312520271665/0001193125-20-271665-index.htm
2020-10-286-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1340243/000119312520279129/0001193125-20-279129-index.htm
2020-11-056-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1340243/000119312520286140/0001193125-20-286140-index.htm
2020-11-056-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1340243/000119312520286193/0001193125-20-286193-index.htm
2019-04-15S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1340243/000134100419000265/0001341004-19-000265-index.htm
2019-11-05S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1340243/000134100419000543/0001341004-19-000543-index.htm
2020-04-22S-8 POSSecurities to be offered to employees in employee benefit plans, post-effective amendmentshttps://www.sec.gov/Archives/edgar/data/1340243/000134100420000144/0001341004-20-000144-index.htm
2020-10-21S-8 POSSecurities to be offered to employees in employee benefit plans, post-effective amendmentshttps://www.sec.gov/Archives/edgar/data/1340243/000134100420000405/0001341004-20-000405-index.htm